Teva buys Auspex for $3.2 billion

Israel’s Teva has bought US biotech Auspex for $3.2 billion and acquires Auspex’s portfolio of innovative medicines for people who live with movement disorders. Auspex also has pipeline treatments for Huntington’s disease, Parkinson’s, dyskensia and Tourette’s syndrome.{F45C98FD-CEA7-48C4-B9CB-A6BD00D0BEDB}

This entry was posted in Economy & Business. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *